leukaemia
ViroCell and UCL launch trial to treat childhood leukaemia relapse
April 24, 2025Research and Development Oncology, UCL, ViroCell, acute lymphoblastic leukaemia, cell therapy, clinical trial, leukaemia
ViroCell Biologics has manufactured a GMP-grade lentiviral vector for a University College London (UCL) clinical trial aimed at tackling relapse …
Qlucore and Sahlgrenska Hospital sign agreement for ALL diagnosis software
January 17, 2024Business Services Oncology, Qlucore, Sahlgrenska Hospital, acute lymphoblastic leukaemia, leukaemia
Qlucore has announced that it has entered into an agreement with Sahlgrenska Hospital, in Gothenberg, Sweden. This agreement means the …
Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment
December 4, 2023Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …
Astellas Pharma and BMT CTN announce phase 3 data for gilteritinib
June 9, 2023Research and Development Astellas Pharma, BMT CTN, Haematology, gilteritinib, leukaemia, pharmaceutical
Japanese pharmaceutical company Astellas Pharma and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) have presented their phase …
NICE recommendation for AstraZeneca’s Calquence in chronic lymphocytic leukaemia populations
December 8, 2020Manufacturing and Production, Sales and Marketing AstraZeneca, NHS, NICE, UK, leukaemia
The National Institute for Health and Care Excellence (NICE) has recommended that AstraZeneca’s Calquence (acalabrutinib) be used on the NHS in …
NICE recommends venetoclax combo, a non-chemo option for untreated chronic lymphocytic leukaemia
November 10, 2020Manufacturing and Production, Sales and Marketing AbbVie, NHS, NICE, UK, leukaemia, venetoclax
NICE has recommended venetoclax in combination with obinutuzumab under final draft guidance for the first-line treatment of untreated chronic lymphocytic …
AbbVie’s Venclexta plus azacitidine shows improved survival and remissions rates in leukaemia patients
June 15, 2020Sales and Marketing AbbVie, leukaemia
AbbVie have announced positive results from its latest Phase 3 clinical trial where Venclexta plus azacitidine improved survival and remission …
Gilead’s magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at ASCO 2020
June 1, 2020Research and Development, Sales and Marketing ASCO 2020, Cancer, Gilead, leukaemia, magrolimab
Gilead took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to unveil new Phase 1b …
Leukaemia drug nilotinib shows promise against Alzheimer’s in small clinical study
May 29, 2020Medical Communications Alzheimer's, leukaemia
The leukemia drug nilotinib has shown promise in reducing the effects of Alzheimer’s disease and while having safe and minimal …
AbbVie’s Imbruvica scoops up 11th FDA approval with chronic lymphocytic leukaemia/small lymphocytic lymphoma nod
April 22, 2020Research and Development, Sales and Marketing Cancer, FDA, imbruvica, leukaemia
AbbVie’s Imbruvica (ibrutinib) has scored its 11th FDA approval, this time in combination with rituximab for the treatment of chronic …
Researchers modify T-cells to identify and target multiple sites on leukaemia cells
April 1, 2020Research and Development Cancer, Cancers, children cancer, leukaemia
Scientists from the Children’s Hospital of Los Angeles have engineered T-cells to identify and target multiple sites on acute lymphoblastic …
AstraZeneca’s trial of leukaemia drug Calquence yields positive results
December 9, 2019Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3
AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …
Sanofi acquires biotech firm Synthorx for $2.5 billion
December 9, 2019Sales and Marketing Genetic Alphabet, Sanofi, acute lymphoblastic leukaemia, leukaemia
Sanofi has agreed to buy California-based biotechnology firm Synthrox, in a deal worth about $2.5 billion (£1.95 billion). Paul Hudson, …
FDA approves AstraZeneca’s Calquence in chronic lymphoma
November 25, 2019Sales and Marketing Astrazenaca, Calquence, FDA, Health Canada, leukaemia, oncology
The FDA has approved AstraZeneca’s BTK inhibitor Calquence (acalabrutinib) in the treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic …
European approval announced for Astellas’ Xospata in FLT3+ treatment-resistant acute myeloid leukaemia
October 28, 2019Sales and Marketing Astellas, Xospata, leukaemia, pharma
Astellas has revealed that the European Commission has awarded marketing approval for Xospata (gilteritinib) as an oral, once-daily monotherapy for …
Latest content
